- Home
- NAD vs HAE Comparison
NAD vs HAE Comparison
Compare NAD & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAD
- HAE
- Stock Information
- Founded
- NAD 1999
- HAE 1971
- Country
- NAD United States
- HAE United States
- Employees
- NAD N/A
- HAE N/A
- Industry
- NAD Investment Managers
- HAE Medical/Dental Instruments
- Sector
- NAD Finance
- HAE Health Care
- Exchange
- NAD Nasdaq
- HAE Nasdaq
- Market Cap
- NAD 2.8B
- HAE 2.5B
- IPO Year
- NAD N/A
- HAE 1991
- Fundamental
- Price
- NAD $11.97
- HAE $50.29
- Analyst Decision
- NAD
- HAE Buy
- Analyst Count
- NAD 0
- HAE 8
- Target Price
- NAD N/A
- HAE $76.88
- AVG Volume (30 Days)
- NAD 595.7K
- HAE 604.2K
- Earning Date
- NAD 01-01-0001
- HAE 11-06-2025
- Dividend Yield
- NAD 4.35%
- HAE N/A
- EPS Growth
- NAD N/A
- HAE 46.89
- EPS
- NAD N/A
- HAE 3.28
- Revenue
- NAD N/A
- HAE $1,346,046,000.00
- Revenue This Year
- NAD N/A
- HAE N/A
- Revenue Next Year
- NAD N/A
- HAE $6.35
- P/E Ratio
- NAD N/A
- HAE $15.34
- Revenue Growth
- NAD N/A
- HAE 0.91
- 52 Week Low
- NAD $9.56
- HAE $47.32
- 52 Week High
- NAD $11.64
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- NAD 63.44
- HAE 47.23
- Support Level
- NAD $11.82
- HAE $49.00
- Resistance Level
- NAD $11.87
- HAE $50.34
- Average True Range (ATR)
- NAD 0.09
- HAE 1.20
- MACD
- NAD 0.00
- HAE 0.16
- Stochastic Oscillator
- NAD 80.95
- HAE 49.01
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.